“With tepotinib improved quality of life for patients”

(beraking latest news) – Silvia Novello, full professor of medical oncology at the Oncology department of the University of Turin and president of Women Against Lung Cancer in Europe (WALCE), spoke at the press conference in which Merck announced that The Italian Medicines Agency has approved for reimbursement tepotinib, a new drug for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with genetic alterations that cause exon 14 skipping of the mesenchymal transition factor epithelial (METex14).